 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12...7891011121314151617...3132» |
- | teriflunomide / Generic mfg., leflunomide / Generic mfg.
Journal, Monotherapy: Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels. (Pubmed Central) - Mar 11, 2022
We obtained the following utility values with the cut-off of A77 1726 > 10 µg/mL to identify RA patients who achieved a DAS28-ESR ≤ 3.2: sensitivity of 91.31%; specificity of 73.91%; positive predictive value of 70.00%; and negative predictive value of 92.73%. Serum A77 1726 discriminated between RA patients who remained with moderate/severe disease activity despite the treatment with LEF both as monotherapy and LEF as combo therapy.
- Profile of Patients with Multiple Sclerosis on Oral Disease-Modifying Therapies While Enrolled in North American Registry for Care and Research in Multiple Sclerosis (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1730;
Our results suggest that real-world patients on oral DMTs are similar to MS patients overall. As MS registries are growing, capturing high-quality, long-term data is increasingly important as more treatment options become available.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Lemtrada (alemtuzumab) / Sanofi
Efficacy of FDA-Approved Disease-Modifying Therapies (DMTS) Versus Active Comparator Medications for Relapsing-Remitting Multiple Sclerosis: A Systematic Review (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1208;
Of the FDA-approved DMTs evaluated in this review, all provided a significant clinical benefit for relapse rate reduction over comparator DMTs. Since comparators differed, further comparison studies, either clinical trials or observational studies, are warranted.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg., fingolimod / Generic mfg.
Factors Associated with Prescribing of Teriflunomide and Dimethyl Fumarate Versus Fingolimod in Multiple Sclerosis (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_424;
The study found that DMF is the most prescribed oral DMA for MS. Patients’ predisposing (age group and region), enabling (insurance), and need factors (comorbidities and neurologist consultation) influenced the selection of specific DMA.
- Comparative Adherence Trajectories across Oral Disease-Modifying Agents in Multiple Sclerosis () - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_14;
Teriflunomide and dimethyl fumarate were associated with poorer adherence trajectories than fingolimod. More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs for the management of MS.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Cost-Effectiveness of Ofatumumab in Comparison with Teriflunomide for Relapsing Multiple Sclerosis Treatment in China: From Both Healthcare System and Societal Perspectives () - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_9;
From the healthcare system perspective, ofatumumab is cost-effective at the threshold of 2-times GDP per capita in China. When considering productivity loss, ofatumumab can reduce social burden and be both clinically superior and cost saving.
- Mavenclad (cladribine) / EMD Serono
Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3903;
For all three pairwise comparisons, relapse and discontinuation outcomes significantly favoured CladT over other oral DMTs. Future analyses with longer follow-up comparing disability progression events are warranted.
- teriflunomide / Generic mfg.
Function of miRNA profiled in Teriflunomide treated multiple sclerosis (MS) patients (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3877;
Despite various studies describing immuno regulatory functions of miR-21 and miR-34 we did not see statistically significant functional changes due to inhibition of miR-21 and miR-34 in T-cells and monocytes profiles when compared to negative inhibition control. Potential reasons are that miR-21 and miR-34 functionality maybe independent of the immune cells we studied in healthy controls.
- Utuxin (ublituximab) / TG Therap
Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3833;
Potential reasons are that miR-21 and miR-34 functionality maybe independent of the immune cells we studied in healthy controls. ULTIMATE I and II post hoc pooled analyses demonstrated a consistent NEDA benefit for ublituximab-treated patients across treatment epochs and key patient subpopulations.
- Lemtrada (alemtuzumab) / Sanofi
Two-Year Interim Analysis of the TREAT-MS Alemtuzumab Study in Germany Differentiated by Direct Pretreatment (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3762;
Hereof, 17.0% (n=84) were treatment-naïve and 83% received the following last previous therapy prior to alemtuzumab: fingolimod (28.5%, n=141), natalizumab (21.1%, n=104), basic injectables (glatiramer acetate or interferon-beta; 20.6%, n=102), or basic orals (dimethyl fumarate or teriflunomide; 12.8%, n=63)... These interim results indicate that alemtuzumab shows good real-world effectiveness and safety across patient subgroups with different pretreatment history but less pronounced effects after fingolimod pretreatment.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Diroximel Fumarate (DRF) Has High Rates of Real-World Adherence and Persistence in Patients with Multiple Sclerosis (MS): Retrospective Claims Analysis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3761;
Adherence rates were high throughout time on treatment for patients on DRF. Outcomes for DRF are consistent with or higher than those for other DMTs observed in the same treatment period.Study Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
Dimethyl Fumarate Demonstrates Treatment Effectiveness in Patients One Year After Switching From Teriflunomide (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3750;
P=N/A, P4
DMF is an effective therapeutic strategy for patients previously treated with teriflunomide regardless of if switching for efficacy or non-efficacy reasons. Study Supported by: Biogen
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
COVID19 infections in patients with Multiple Sclerosis (MS) on Various treatments at Kaiser Permanent Mid-Atlantic States (KPMAS) (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3673;
We found that the rates of COVID19 infection in patients with MS in the BDT group were not out of proportion when compared to those on other treatments for MS. The poor outcomes were more likely to be related to underlying comorbidities.
- Mayzent (siponimod) / Novartis
Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of Relapsing Multiple Sclerosis: Interim Results of the Phase 3b EXCHANGE Study (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3615;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety/tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Data from Clinical Studies and Post Marketing Experience (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3613;
Systemic and local-site IRRs reported upon first injection with ofatumumab in the ALITHIOS trial and post-marketing surveillance were mostly mild-to-moderate in severity. These results are consistent with the Phase 3 ASCLEPIOS I/II trials.
- remibrutinib (LOU064) / Novartis
Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3607;
These results are consistent with the Phase 3 ASCLEPIOS I/II trials. The REMODEL I and II studies will investigate the efficacy, safety and tolerability of remibrutinib versus teriflunomide to support regulatory approval worldwide as a potential new oral treatment for patients with this disabling disease.
- Utuxin (ublituximab) / TG Therap
Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3125;
Ublituximab provided significantly improved efficacy vs teriflunomide in ULTIMATE I and II. IRRs were the prevailing adverse event with ublituximab in ULTIMATE I and II; the majority occurred at the first dose and had minimal impact on infusion completion, and pyrexia was the most common.
- teriflunomide / Generic mfg.
Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2791;
P3
IRRs were the prevailing adverse event with ublituximab in ULTIMATE I and II; the majority occurred at the first dose and had minimal impact on infusion completion, and pyrexia was the most common. The result of this study investigating the impact of early treatment of teriflunomide in RIS will be published at the end of 2022.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Long-term Efficacy of Ofatumumab in Patients With Relapsing Multiple Sclerosis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2790;
The result of this study investigating the impact of early treatment of teriflunomide in RIS will be published at the end of 2022. These analyses will provide insights on the sustained efficacy of continuous ofatumumab treatment for up to 4 years in patients with RMS, and also on the efficacy of ofatumumab in patients newly switched from teriflunomide.
- Ponvory (ponesimod) / J&J
Effect of Ponesimod Compared With Teriflunomide on Treatment With Concomitant Corticosteroids for Relapse in Patients with Relapsing Forms of Multiple Sclerosis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2786;
P3
In addition, we assessed the mean accumulated steroid dose (prednisone equivalent doses in mg) administered to treat relapse between start of study treatment and EOS. In the OPTIMUM trial, patients with RMS treated with PON achieved a lower rate of concomitant SCS usage for the management of relapses compared with patients treated with TER.
- Utuxin (ublituximab) / TG Therap
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2785;
In the OPTIMUM trial, patients with RMS treated with PON achieved a lower rate of concomitant SCS usage for the management of relapses compared with patients treated with TER. Along with the prespecified 12- and 24-week CDI analyses, post-hoc evaluations of sustained 12-week CDI, 9-HPT, and T25FW provide further evidence of clinically meaningful disability improvement with ublituximab in ULTIMATE I and II.
- dimethyl fumarate / Generic mfg.
Trajectories of disability and relapse-rate in naïve patients on oral drugs: results from the Italian Multiple Sclerosis Register (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2429;
Design/ This retrospective observational cohort included treatment-naive patients from the Italian MS registry, starting fingolimod (FIN), teriflunomide (TER) or dimethyl fumarate (DMF), followed-up for 5 years, with ≥1 EDSS per year... In our real-life cohort, the three oral DMTs showed a similar long-term effect on disability progression, while FIN proved to be more effective on relapse-rate.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Patterns of Healthcare Utilization and Expenditure among People with Multiple Sclerosis in the Age of Disease-Modifying Therapy: An Analysis of Claim Data from a Commercially Insured Population in the United States, 2010-2019 (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2426;
Design/ In a retrospective analysis using claims data from a commercially insured population (2010-2019), we assigned patients to treatment arms based on DMTs received during the coverage period: no DMT (ND), high-efficacy (HE) (alemtuzumab, B-cell depletion, cladribine, natalizumab), and standard-efficacy (SE) DMT (dimethyl fumarate, glatiramer acetate, interferon-beta, sphingosine-1-phosphate receptor modulator, teriflunomide)... DMT cost is a key driver of the healthcare expenditure in MS, highlighting the need for prospective comparative studies towards value-based medicine.
- Ponvory (ponesimod) / J&J
Analysis and Evaluation of Ponesimod Hepatic Safety Data ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2067;
Objective: In the phase III OPTIMUM study, we evaluated alanine transaminase (ALT) elevations with ponesimod 20mg compared with teriflunomide 14mg. The pattern of hepatic effects observed with ponesimod treatment in the development program is consistent with the S1P class and no cautionary statement on adverse reactions for moderate and severe hepatic impairment categories was included in the label.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Serum NfL and GFAP biomarker analysis in early high versus low efficacy DMT paradigms for MS ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2055;
In cohort A, with pretreatment levels, sNFL and sGFAP trended to decrease more rapidly in HEET compared to LEET. Thus, pretreatment biomarkers followed longitudinally may inform prognostication and monitoring of the HEET or LEET approach; additional randomized studies are necessary.
- Ponvory (ponesimod) / J&J
Relationships Between Brain Volume and Disability, Cognition, Motor Function, and MS-Fatigue in Relapsing Multiple Sclerosis: MS-Fatigue and Ambulation Move at Their Own Pace ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2034;
Design/ Patients received ponesimod (20mg) or teriflunomide (14mg) over 108 weeks. There are statistically significant relationships between BV and clinical outcome measures of disability, cognition, motor function, and MS-fatigue; however, ambulation and MS-fatigue were not associated with the PBVC.
- Utuxin (ublituximab) / TG Therap
Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2031;
There are statistically significant relationships between BV and clinical outcome measures of disability, cognition, motor function, and MS-fatigue; however, ambulation and MS-fatigue were not associated with the PBVC. In the Phase 3 ULTIMATE I and II trials, relapse rate and cumulative probability of relapse were significantly reduced with ublituximab vs teriflunomide.
- Ponvory (ponesimod) / J&J
Ponesimod Shows Improved Effect on Brain Volume Compared with Other DMTs, A Model Based Meta-Analysis ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1983;
Based on the MBMA results, ponesimod, the only monospecific S1P1 receptor modulator, has shown improved brain volume data compared to other MS DMTs. Additional studies looking at direct CNS effects of ponesimod could help to further explain its beneficial effect on BVL.
- dimethyl fumarate / Generic mfg.
Impact of Covid-19: Preserving Services for Patients with Multiple Sclerosis during a Global Pandemic. ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1859;
Whilst most patients experienced normal standard care, Covid-19 has impacted service provision for some pwMS, with delays reported across a multi-faceted service. The downstream effects of this may be seen moving beyond the pandemic.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1752;
Ofatumumab was dominant (more efficacy, lower costs) over first-line DMTs teriflunomide, interferons, dimethyl fumarate, and ocrelizumab, and resulted in incremental cost-effectiveness ratios (ICERs) of $24,177 Canadian dollars per quality-adjusted life-years (QALYs) gained versus glatiramer acetate and $28,034 versus BSC... Ofatumumab is cost effective against all comparators and dominant against all currently approved and reimbursed first-line DMTs for RRMS, except glatiramer acetate.
- Mavenclad (cladribine) / EMD Serono
Cladribine Tablets in Patients With Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1733;
At datacut, CLICK-MS and MASTER-2 have enrolled patients switching from a variety of DMTs. TEAEs reported were low in frequency and severity, and did not lead to treatment discontinuation.
- Ponvory (ponesimod) / J&J
Analysis of Post-treatment Relapse Activity in the Phase 3 OPTIMUM Study of Ponesimod Compared with Teriflunomide ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1679;
TEAEs reported were low in frequency and severity, and did not lead to treatment discontinuation. These prospectively obtained post-treatment observation data in patients who stopped ponesimod treatment in the OPTIMUM study, do not support increased early post-treatment relapse activity as compared to activity on treatment.
- Mayzent (siponimod) / Novartis
AMA-VACC: Clinical trial assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod treated patients with secondary progressive multiple sclerosis ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1676;
Cohort 1 receives SARS-CoV-2 mRNA vaccination while continuing their current siponimod treatment, cohort 2 interrupts siponimod treatment for the purpose of a full vaccination cycle and cohort 3 receives vaccination during continuous treatment with first-line DMTs (glatirameracetate, interferons, teriflunomide) or no current treatment in clinical routine. This analysis will provide first longitudinal data on the immune response after SARS-CoV-2 mRNA vaccination in siponimod treated SPMS patients and enable physicians and patients to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Long-term Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis () - Mar 6, 2022 - Abstract #AAN2022AAN_1592;
Safety findings for up to 3.5 years showed ofatumumab treatment to be well-tolerated with no new safety risks identified. This additional safety data will help confirm ofatumumab’s longer-term safety profile and provide further confidence to the MS community.
- Mavenclad (cladribine) / EMD Serono
Impact of Multiple Sclerosis Disease-Modifying Therapies on Effectiveness of SARS-Cov-2 Vaccines: A Longitudinal Total Population Study of National Health Service (NHS) England () - Mar 6, 2022 - Abstract #AAN2022AAN_1489;
The changes associated with other DMTs are less clear. Further analysis of data collected longitudinally over a longer period will reveal their impact on the effectiveness of SARS-CoV-2 vaccines.
- Lemtrada (alemtuzumab) / Sanofi, Spikevax (elasomeran) / Moderna, Takeda
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review and meta-analysis () - Mar 6, 2022 - Abstract #AAN2022AAN_1488;
Humoral responses appear to be blunted in S1PM and anti-CD20 treatments; however, the majority develop cellular responses. Further investigation into how DMT affects immune response are needed.
- Utuxin (ublituximab) / TG Therap
Relapse Rate and Time to First Relapse Were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS) ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1320;
- ||| Lemtrada (alemtuzumab) / Sanofi
Journal, Adverse events: Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. (Pubmed Central) - Mar 4, 2022
P
All consecutive reports of DMTs prescribed to pwMS (alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon-β, natalizumab, ocrelizumab, and teriflunomide), and their serious adverse event cases were eligible, excluding those reporting immunosuppressant DMTs used as anticancer therapies...A close and regular cancer screening in pwMS treated with natalizumab, interferon-β, dimethyl fumarate, and fingolimod may be warranted, even for persons at a younger age. Trial Registration NCT04237337.
- ||| teriflunomide / Generic mfg.
Clinical, Review, Journal, Adverse events: Severe bone pain with teriflunomide: Five case reports and review of the French pharmacovigilance database. (Pubmed Central) - Mar 3, 2022
Trial Registration NCT04237337. No abstract available
- ||| Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal, Adverse events: Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature. (Pubmed Central) - Mar 3, 2022
However, longitudinal studies regarding ocular TEAEs related to multiple sclerosis therapy are necessary to provide evidence-based recommendations, especially in understudied regions such as Latin America and Africa. Physicians should monitor ocular symptoms in patients being treated for multiple sclerosis and consider an interdisciplinary approach.
- || teriflunomide / Generic mfg.
Clinical, Journal, Real-world evidence: Serological markers exploration and real-word effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis. (Pubmed Central) - Mar 3, 2022
Teriflunomide can significantly reduce the concentrations of inflammatory cytokines, indicating that teriflunomide may regulate neuroinflammation through the inhibitory effect on a variety of immune cells and their cytokines. Teriflunomide can improve clinical symptoms and disease severity in MS patients in southern China, and patients have good compliance.
- || Mavenclad (cladribine) / EMD Serono
Clinical, Journal: Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. (Pubmed Central) - Mar 3, 2022
Humoral response to BNT162b2-mRNA-vaccine was increased in IFN-treated MS subjects while clearly blunted in those under CLAD, FTY and OCRE treatment. This suggests that the DMTs could have a key role in the protection from SARS-CoV-2 related disease and complication in MS subjects, underlying a novel aspect that should be considered in the selection of the most appropriate therapy under COVID-19 pandemic.
- || teriflunomide / Generic mfg., leflunomide / Generic mfg.
Clinical, Journal: Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment. (Pubmed Central) - Mar 3, 2022
This suggests that the DMTs could have a key role in the protection from SARS-CoV-2 related disease and complication in MS subjects, underlying a novel aspect that should be considered in the selection of the most appropriate therapy under COVID-19 pandemic. The common susceptibility genes and drug target genes among MS, SLE, and RA provide a theoretical basis for the co-morbidity phenomenon of the three diseases in clinical practice and may guide the clinical treatment.
- || dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
Clinical, Journal, Real-world evidence: Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. (Pubmed Central) - Mar 3, 2022
The common susceptibility genes and drug target genes among MS, SLE, and RA provide a theoretical basis for the co-morbidity phenomenon of the three diseases in clinical practice and may guide the clinical treatment. TERI and DMF have similar effectiveness and rate of discontinuation when employed as first therapeutic choice in RRMS patients.
- | teriflunomide / Generic mfg.
Journal: Gastrointestinal pathologic findings of teriflunomide associated diarrhea. (Pubmed Central) - Mar 3, 2022
TERI and DMF have similar effectiveness and rate of discontinuation when employed as first therapeutic choice in RRMS patients. This is the first reported case of small intestinal inflammation similar to celiac disease in teriflunomide associated diarrhea.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America. (Pubmed Central) - Feb 23, 2022
The most common challenge and barrier identified was the cost of medications. The present study allows an understanding of the delivery of care for MS and NMOSD in the region.
- ||| glatiramer acetate / Generic mfg., teriflunomide / Generic mfg.
Clinical, Journal, Adverse events: Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report. (Pubmed Central) - Feb 23, 2022
Teriflunomide-induced liver injury in patients with multiple sclerosis is a serious adverse reaction. The report of this case contributes to updating knowledge about the safety aspects of treatment with teriflunomide and planning of monitoring strategies and patient risk management.
- Lemtrada (alemtuzumab) / Sanofi
Breast Cancer in Multiple Sclerosis Patients Treated with Disease Modifying Therapies (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_550;
Further examination of odds ratios showed additional increases with INFb1a and NAT. The lowest proportions were reported with ALE and FIN; however, further examination of odds ratios showed decreases with INFb1b, GA, TER, and ALE.
- teriflunomide / Generic mfg.
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: a real-world multicenter analysis (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_546;
Safety results suggest overall stability with a potential reduction of lymphopenia. †Most patients were administered teriflunomide 14 mg.
- dimethyl fumarate / Generic mfg.
Effect of the disease modifying agents on the disease progression, radiological profile and subcortical grey matter volume in Multiple Sclerosis (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_530;
100% on NTZ & 90% patients on RTX had decrease in MRI lesions are more efficacious compared with DMF. SCGMA (thalamus>pallidum) is more with RTX than NTZ.